BR112023023086A2 - Anticorpo anti-5t4, composição, sequência de polinucleotídeos isolada, vetor, célula hospedeira, e, método de tratamento de uma doença - Google Patents

Anticorpo anti-5t4, composição, sequência de polinucleotídeos isolada, vetor, célula hospedeira, e, método de tratamento de uma doença

Info

Publication number
BR112023023086A2
BR112023023086A2 BR112023023086A BR112023023086A BR112023023086A2 BR 112023023086 A2 BR112023023086 A2 BR 112023023086A2 BR 112023023086 A BR112023023086 A BR 112023023086A BR 112023023086 A BR112023023086 A BR 112023023086A BR 112023023086 A2 BR112023023086 A2 BR 112023023086A2
Authority
BR
Brazil
Prior art keywords
antibody
vector
disease
composition
host cell
Prior art date
Application number
BR112023023086A
Other languages
English (en)
Portuguese (pt)
Inventor
Liat Dassa
Oren Bogin
Original Assignee
Immunorizon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunorizon Ltd filed Critical Immunorizon Ltd
Publication of BR112023023086A2 publication Critical patent/BR112023023086A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023023086A 2021-05-04 2022-05-02 Anticorpo anti-5t4, composição, sequência de polinucleotídeos isolada, vetor, célula hospedeira, e, método de tratamento de uma doença BR112023023086A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163183636P 2021-05-04 2021-05-04
PCT/IL2022/050451 WO2022234570A1 (en) 2021-05-04 2022-05-02 Anti-5t4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112023023086A2 true BR112023023086A2 (pt) 2024-01-30

Family

ID=83932628

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023086A BR112023023086A2 (pt) 2021-05-04 2022-05-02 Anticorpo anti-5t4, composição, sequência de polinucleotídeos isolada, vetor, célula hospedeira, e, método de tratamento de uma doença

Country Status (11)

Country Link
US (1) US20240228658A1 (enExample)
EP (1) EP4334362A4 (enExample)
JP (1) JP2024517760A (enExample)
KR (1) KR20240004837A (enExample)
CN (1) CN117279951A (enExample)
AU (1) AU2022270453A1 (enExample)
BR (1) BR112023023086A2 (enExample)
CA (1) CA3217716A1 (enExample)
IL (1) IL308203A (enExample)
MX (1) MX2023013018A (enExample)
WO (1) WO2022234570A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026510761A (ja) * 2023-03-08 2026-04-10 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 抗５ｔ４抗体及びその使用
WO2024208145A1 (zh) * 2023-04-03 2024-10-10 非同（成都）生物科技有限公司 抗5t4抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009709A1 (en) * 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
US10035847B2 (en) * 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
MX384198B (es) * 2014-12-19 2025-03-14 Chiome Bioscience Inc Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
MA52152A (fr) * 2018-03-12 2021-01-20 Genmab As Anticorps
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法

Also Published As

Publication number Publication date
MX2023013018A (es) 2024-01-18
WO2022234570A1 (en) 2022-11-10
IL308203A (en) 2024-01-01
CN117279951A (zh) 2023-12-22
AU2022270453A1 (en) 2023-12-21
US20240228658A1 (en) 2024-07-11
KR20240004837A (ko) 2024-01-11
EP4334362A4 (en) 2025-04-16
JP2024517760A (ja) 2024-04-23
EP4334362A1 (en) 2024-03-13
CA3217716A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
CO2021006248A2 (es) Anticuerpos anti-nkg2a y usos de los mismos
ECSP19010852A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso
BR112019023992A2 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
BR112022024483A2 (pt) Métodos para tratar mieloma múltiplo
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112018075737A2 (pt) anticorpo, composição, célula isolada, e, métodos para tratar câncer ou infecção em um paciente e para detectar expressão de pd-l1 em uma amostra.
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
ES2675375T3 (es) Anticuerpos monoclonales contra claudina 18 para el tratamiento del cáncer
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
MY205967A (en) Monoclonal antibodies against the beta chain region of human trbv9
MX2021001517A (es) Terapia basada en microarn dirigida contra canceres positivos para proteina citosolica de linfocito 1 (lcp-1).
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9
BR112022021871A2 (pt) Polipeptídeo car, composição, ácido nucleico, célula imune, método para tratar um tumor, e, banco de células
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
BR102014029197A8 (pt) conjugado, seu processo de obtenção, uso, composição farmacêutica, ácido nucléico, vetor e célula hospedeira.
BR112021017860A2 (pt) Anticorpo ou fragmento de anticorpo isolado específico para c5ar de humano, composição de ácido nucleico, composição de vetor, célula hospedeira e composição farmacêutica
MY204733A (en) Anti-pd-l1 antibodies and use thereof
BR112019011350A2 (pt) terapia de combinação
EA201991870A1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
BR112021005365A2 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo, anticorpo biespecífico, composição, um ou mais polinucleotídeos, célula isolada, método para tratar câncer ou infecção, e, uso do anticorpo ou fragmento do mesmo ou da composição